Actavis offered $219 per share in cash and stock, and its shares rose 1.7 percent to $247.94. The deal, however, also included $400 million in research and development cuts for Allergan. The new company will operate from both California, where Allergan is based, and New Jersey, where Actavis is headquartered.
Actavis is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and innovative branded pharmaceutical products.
Valeant Pharmaceuticals International was also in the running acquire Allergan, however the company settled for Actavis’ offer, according to the report.
More articles on gastroenterology:
Cantel Medical names Jorgen Hansen president, COO
Hanover Gastroenterology expands
GI physician to know: Dr. David Rubin of University of Chicago Medicine
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.